logo
Plus   Neg
Share
Email

BorgWarner Slashes FY20 Net Sales Outlook Amid COVID-19 - Quick Facts

While reporting financial results for the first quarter on Wednesday, technology solutions provider BorgWarner Inc. (BWA) slashed its net sales guidance for the full-year 2020 as global light vehicle production expectations remain volatile due to the impact of coronavirus (COVID-19).

For fiscal 2020, the company now projects net sales between $7.25 billion and $8.0 billion, implying year-over-year organic sales decline of 20 to 27 percent.

Previously, the company expected net sales between $9.750 billion and $10.075 billion, implying year-over-year organic sales change between about down 2.5 percent and up 0.5 percent.

On average, analysts polled by Thomson Reuters expect the company to report net sales of $8.51 billion for the year. Analysts' estimates typically exclude special items.

This guidance is for BorgWarner as currently consolidated and excludes the potential impact from the acquisition of Delphi Technologies PLC, which BorgWarner is announcing on January 28, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT